click above for the report, released at AIDS 2008 in Mexico City
1 comment:
Anonymous
said...
For a little rectal microbicide context, while the total 2007 global investment in HIV vaccine R&D was $961 million, and total investment in microbicides was $226.5 million - the investment for rectal microbicides was around $7 million - per 2006 numbers. The report does not differentiate between vaginal and rectal expenditures.
IRMA would like to see more clarity and detail in the reporting of microbicide investments in the future, and would like to help make that happen! It is important to know where the money is going, and how it is being used.
The report does include a special highlighted box on RMs and reads like this -
Rectal Microbicide Research Moves Forward
The Working Group does not track vaginal and rectal microbicide separately, as very few donors differentiate their funding in this regard. Basic and pre-clinical research can potentially benefit both possible applications, while clinical trials are mostly exploring vaginal microbicides.
The year 2007, however, brought the launch of the first rectal microbicide safety trial—a Phase I randomized, blinded, placebo-controlled safety and acceptability study of the UC-781 microbicide gel formulation applied rectally in HIV-1 sero-negative adults. Looking ahead, two more Phase I trials are poised to begin testing the rectal safety of tenofovir gel and the gel PRO 2000 in 2008. Other completed or ongoing research includes development of the product pipeline, behavioral studies examining anal sexual practices, development of rectal applicators, establishment of colorectal baseline measurements, and the safety profile for sexual lubricants.
This activity is due in part to funding from the National Institute of Allergy and Infectious Diseases and amfAR, and to the formation of the International Rectal Microbicide Advocates (IRMA). In 2004, NIAID allocated its first five-year rectal microbicide grant, totaling $17.6 million and averaging $3.5 million a year in allocations. The monies were distributed to researchers by way of the U-19 Microbicide Development Program. The program focuses primarily on translational work to advance research into clinical trials, and is headed by the University of California, Los Angeles (UCLA). Other funders of rectal microbicide research include: amfAR, the Foundation for AIDS Research, the US Centers for Disease Control, the UK’s Medical Research Council, the National Institute of Child Health and Human Development, the NIH Sexually Transmitted Infections Clinical Trial Group, and the Population Council. For more information about recent trends and needs in rectal microbicide research, see IRMA’s recent report Less Silence, More Science.
1 comment:
For a little rectal microbicide context, while the total 2007 global investment in HIV vaccine R&D was $961 million, and total investment in microbicides was $226.5 million - the investment for rectal microbicides was around $7 million - per 2006 numbers. The report does not differentiate between vaginal and rectal expenditures.
IRMA would like to see more clarity and detail in the reporting of microbicide investments in the future, and would like to help make that happen! It is important to know where the money is going, and how it is being used.
The report does include a special highlighted box on RMs and reads like this -
Rectal Microbicide Research Moves Forward
The Working Group does not track vaginal and rectal microbicide separately, as very few donors differentiate their funding in this regard. Basic and pre-clinical research can potentially benefit both possible applications, while clinical trials are mostly exploring vaginal microbicides.
The year 2007, however, brought the launch of the first rectal microbicide safety trial—a Phase I randomized, blinded, placebo-controlled safety and acceptability study of the UC-781 microbicide gel formulation applied rectally in HIV-1 sero-negative adults. Looking ahead, two more Phase I trials are poised to begin testing the rectal safety of tenofovir gel and the gel PRO 2000 in 2008. Other completed or ongoing research includes development of the product pipeline, behavioral studies examining anal sexual practices, development of rectal applicators, establishment of colorectal baseline measurements, and the safety profile for sexual lubricants.
This activity is due in part to funding from the National Institute of Allergy and Infectious Diseases and amfAR, and to the formation of the International Rectal Microbicide Advocates (IRMA). In 2004, NIAID allocated its first five-year rectal microbicide grant, totaling $17.6 million and averaging $3.5 million a year in allocations. The monies were distributed to researchers by way of the U-19 Microbicide Development Program. The program focuses primarily on translational work to advance research into clinical trials, and is headed by the University of California, Los Angeles (UCLA). Other funders of rectal microbicide research include: amfAR, the Foundation for AIDS Research, the US Centers for Disease Control, the UK’s Medical Research Council, the National Institute of Child Health and Human Development, the NIH Sexually Transmitted Infections Clinical Trial Group, and the Population Council. For more information about recent trends and needs in rectal microbicide research, see IRMA’s recent report Less Silence, More Science.
Post a Comment